ATC code M
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Y-S.Ko (talk | contribs) at 22:30, 26 May 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Pharmaceutical drug classification
ATC code M: Musculo-skeletal system |
---|
|
Other ATC codes |
ATC code M Musculo-skeletal system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QM.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code M". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QM". WHO Collaborating Centre for Drug Statistics Methodology.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism (A) | |
blood and blood forming organs (B) | |
cardiovascular system (C) | |
skin (D) | |
genitourinary system (G) | |
endocrine system (H) | |
infections and infestations (J, P, QI) | |
malignant disease (L01–L02) | |
immune disease (L03–L04) | |
muscles, bones, and joints (M) | |
brain and nervous system (N) |
|
respiratory system (R) | |
sensory organs (S) | |
other ATC (V) | |
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
Specific antirheumatic products / DMARDs (M01C) | |
---|---|
Quinolines | |
Gold preparations | |
Other | |
|
Anti-inflammatory preparations, non-steroids |
| ||||||
---|---|---|---|---|---|---|---|
Capsaicin derivatives | |||||||
Other |
Uricosurics |
| ||||
---|---|---|---|---|---|
Xanthine oxidase inhibitors |
| ||||
Mitotic inhibitors | |||||
Other | |||||
|
Drugs for treatment of bone diseases (M05) | |
---|---|
Bisphosphonates | |
Bone morphogenetic proteins | |
Other |
|
Other drugs for disorders of the musculo-skeletal system (M09) | |
---|---|
Quinine and derivatives | |
Enzymes | |
Gene therapies | |
Antisense oligonucleotides | |
Glucocorticoids | |
Histone deacetylase inhibitors | |
Other | |
|